These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 33879671)
1. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study. Zhang L; Liu Z; Zhu J Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671 [TBL] [Abstract][Full Text] [Related]
2. Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis. Liu Q; Song X; Liu Z; Yu Z Technol Cancer Res Treat; 2021; 20():15330338211019506. PubMed ID: 34184566 [TBL] [Abstract][Full Text] [Related]
3. miRNA-135b Contributes to Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243 [TBL] [Abstract][Full Text] [Related]
4. Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines. Privat M; Rudewicz J; Sonnier N; Tamisier C; Ponelle-Chachuat F; Bignon YJ Int J Med Sci; 2018; 15(1):46-58. PubMed ID: 29333087 [TBL] [Abstract][Full Text] [Related]
5. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis. Zhong G; Lou W; Shen Q; Yu K; Zheng Y Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598 [TBL] [Abstract][Full Text] [Related]
6. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337 [TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer. Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064 [TBL] [Abstract][Full Text] [Related]
8. A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer. Liu Q; Wang Z; Kong X; Wang X; Qi Y; Gao R; Fang Y; Wang J DNA Cell Biol; 2020 Apr; 39(4):671-682. PubMed ID: 32040341 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma. Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310 [TBL] [Abstract][Full Text] [Related]
10. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011 [TBL] [Abstract][Full Text] [Related]
11. Characterization of alternative splicing events and prognostic signatures in breast cancer. Han P; Zhu J; Feng G; Wang Z; Ding Y BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836 [TBL] [Abstract][Full Text] [Related]
12. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800 [TBL] [Abstract][Full Text] [Related]
13. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis. Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y Gene; 2020 Jul; 747():144657. PubMed ID: 32298762 [TBL] [Abstract][Full Text] [Related]
15. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890 [TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer. Fang Z; Han YL; Gao ZJ; Yao F Aging (Albany NY); 2024 May; 16(9):8279-8305. PubMed ID: 38728370 [TBL] [Abstract][Full Text] [Related]
17. Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma. Liu J; Liao X; Zhu X; Lv P; Li R Cancer Med; 2020 Oct; 9(19):7018-7033. PubMed ID: 32780509 [TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241 [TBL] [Abstract][Full Text] [Related]
19. Identification and Prognostic Value Exploration of Cyclophosphamide (Cytoxan)-Centered Chemotherapy Response-Associated Genes in Breast Cancer. Du J; Dong Y; Li Y DNA Cell Biol; 2021 Nov; 40(11):1356-1368. PubMed ID: 34704810 [TBL] [Abstract][Full Text] [Related]
20. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma. Zhou JG; Zhao HT; Jin SH; Tian X; Ma H Gynecol Oncol; 2019 Dec; 155(3):499-507. PubMed ID: 31662204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]